Coping with the Ongoing SARS-CoV-2 Pandemic and Seasonal Influenza

Mujahed, Mustafa; Ahmed, Mohammed

doi:10.23937/2474-3658/1510304

Cited by 1 publication

(1 citation statement)

References 17 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To combat respiratory viral infections effectively, we must prioritize research and development efforts [9]. Antibodies have been established as a crucial form of therapeutics due to their valuable benefits, including exceptional specificity and affinity [10].…”

Section: Introductionmentioning

confidence: 99%

Nanobodies as Spray and Aerosol Particles: A Breakthrough in Treating Respiratory Viral Infections

Mustafa,

Mohammed

2023

Preprint

View full text Add to dashboard Cite

Respiratory viral infections, including influenza, respiratory syncytial virus (RSV), and, more recently, the coronavirus disease 2019 (COVID-19) pandemic, continue to pose significant global health threats. Conventional treatments for these infections often face challenges such as limited efficacy, the emergence of drug-resistant strains, and the requirement for frequent administration. In recent years, nanobodies have emerged as a promising class of therapeutic agents due to their unique properties, including small size, high stability, and specific binding capabilities. This mini-review article focuses on the application of nanobodies as spray and aerosol particles for the treatment of respiratory viral infections. Furthermore, we highlight the remarkable efficacy of nanobodies in preclinical and clinical studies against respiratory viruses, including their ability to neutralize viral particles, inhibit viral replication, and modulate the host immune response. We discuss the potential advantages of using nanobodies as inhalable formulations, including their improved delivery to the respiratory tract, enhanced stability in aerosol form, and reduced systemic side effects. Additionally, we explore the various strategies employed to engineer nanobodies for optimal aerosol delivery, such as conjugation to carrier particles or formulation as dry powders. We also examine the potential challenges and limitations associated with the development of nanobody-based aerosol therapies, including production scalability, cost-effectiveness, and regulatory considerations.

show abstract

Section: Introductionmentioning

confidence: 99%